-
Innovation Ranking
NewInnovation Ranking – Arcus Biosciences Inc
Arcus Biosciences Inc (Arcus Biosciences) operates as a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies by leveraging underexploited biological opportunities. Its product pipeline includes AB928, a selective dual antagonist of the adenosine receptors known as A2aR and A2bR in combination with anti-PD-1 antibody (AB122) and chemotherapy is used for the treatment of metastatic triple-negative breast cancer or ovarian cancer and advanced malignancies; AB122, an anti-PD-1 antibody targeting cancer; AB154, an anti-TIGIT antibody; and AB680, a CD73 inhibitor against...
-
Product Insights
NewNet Present Value Model: Arcus Biosciences Inc’s Quemliclustat
Empower your strategies with our Net Present Value Model: Arcus Biosciences Inc's Quemliclustat report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Arcus Biosciences Inc’s Etrumadenant
Empower your strategies with our Net Present Value Model: Arcus Biosciences Inc's Etrumadenant report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Arcus Biosciences Inc’s Domvanalimab
Empower your strategies with our Net Present Value Model: Arcus Biosciences Inc's Domvanalimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Arcus Biosciences Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Arcus Biosciences Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval Analysis for Heterozygous familial hypercholesterolemia (heFH)
Overview How likely is it that the drugs in Heterozygous familial hypercholesterolemia (heFH) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Heterozygous familial hypercholesterolemia (heFH) Overview Heterozygous familial hypercholesterolemia (HeFH) is...
-
Product Insights
NewLikelihood of Approval Analysis for Dyslipidemia
Overview How likely is it that the drugs in Dyslipidemia will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dyslipidemia Overview Dyslipidemia is defined as elevation of the total cholesterol, the "bad"...
-
Product Insights
NewLikelihood of Approval Analysis for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)
Overview How likely is it that the drugs in Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Overview Familial hypercholesterolemia (FH)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Azercabtagene Zapreleucel in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azercabtagene Zapreleucel in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azercabtagene Zapreleucel in Diffuse Large B-Cell Lymphoma Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Azercabtagene Zapreleucel in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azercabtagene Zapreleucel in Mantle Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azercabtagene Zapreleucel in Mantle Cell Lymphoma Drug Details: Azercabtagene...